Compound Monograph — PX13-R
PX13-R
Triple GLP-1 / GIP / glucagon receptor agonist
For laboratory research use only. Not for human or veterinary use.
Compound data
- Compound class
- Triple agonist — GLP-1 / GIP / glucagon receptors
- Structure
- 39-amino-acid synthetic peptide, C20 fatty-diacid side chain
- Molecular formula
- C221H342N46O68
- Molar mass
- ≈ 4,731 g/mol
- CAS number
- 2381089-83-2
- Sequence origin
- GIP-backbone chimera with glucagon and GLP-1 receptor activity
- Presentation
- Lyophilized powder — 10mg, 20mg, 30mg, 60mg vials
- Purity specification
- ≥ 99% by HPLC, identity confirmed by LC-MS
Overview
PX13-R is a synthetic 39-amino-acid peptide engineered as a triple receptor agonist, with activity at the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. It was developed on a GIP peptide backbone and modified with a C20 fatty-diacid side chain that promotes albumin binding, extending its circulating half-life to approximately six days in published pharmacokinetic work.
The addition of glucagon receptor agonism is the defining feature that distinguishes PX13-R from dual agonists such as PX12-T. In the published literature, this triple-agonist profile has been studied for its combined effects on energy intake signaling, energy expenditure, and hepatic metabolism pathways in preclinical and clinical research settings.
Mechanism in the research literature
GLP-1 receptor activity
GLP-1 receptor agonism is the most extensively characterized incretin pathway. In published research it is associated with glucose-dependent insulin secretion signaling, slowed gastric emptying, and central appetite-regulation pathways. PX13-R retains this activity as one arm of its triple-agonist profile.
GIP receptor activity
GIP receptor agonism is the second incretin arm. The research literature describes GIP signaling as complementary to GLP-1 in metabolic models, with published work examining its role in adipose tissue biology and nutrient partitioning.
Glucagon receptor activity
Glucagon receptor agonism is the third and distinguishing arm. Published studies have examined glucagon signaling in the context of hepatic energy handling and energy expenditure pathways — the axis that separates triple agonists from dual agonists in the research literature.
Published research summary
- Phase 2 clinical trial data published in the New England Journal of Medicine (2023) reported dose-dependent changes in body-weight endpoints in studied populations over 48 weeks.
- Published pharmacokinetic characterization supports an approximate six-day half-life consistent with once-weekly administration in research protocols.
- Preclinical work has examined the contribution of the glucagon receptor arm to energy-expenditure signaling relative to dual-agonist comparators.
- Analytical characterization of the compound relies on HPLC purity profiling and LC-MS molecular identity confirmation — the standards applied to every PX13-R batch.
Handling, reconstitution & storage
- Storage (lyophilized)
- -20 °C long term; 2–8 °C short term; protect from light
- Reconstitution
- Bacteriostatic water added slowly down the vial wall; swirl gently, never shake
- Example ratio
- 10mg vial + 2.0 mL diluent = 5 mg/mL (10 units = 500 mcg)
- Stability (reconstituted)
- ≈ 28–30 days refrigerated at 2–8 °C with bacteriostatic water
- Stability (sterile water)
- 24–48 hours refrigerated; no preservative present
- Freeze/thaw
- Avoid repeated freeze/thaw cycling of reconstituted solutions
Frequently asked questions
Research use only. PX13-R (PX13-R) is supplied exclusively as a laboratory research compound. It is not a drug, food, or cosmetic, and it is not intended for human or veterinary administration, diagnostic use, or household use. Statements on this page summarize published scientific literature for reference purposes and do not constitute medical advice or health claims. All PX1 Research batches ship with lot-specific Certificates of Analysis confirming ≥ 99% purity by HPLC and identity by LC-MS.